March 23, 2015
1 min read
Save

Study: Juvéderm demonstrates greater improvement than Belotero in treating perioral lines

SAN FRANCISCO — Juvéderm showed a higher response rate and greater improvement in the treatment of moderate-to-severe perioral lines compared with Belotero, according to research presented at a late-breaking research session during the American Academy of Dermatology Annual Meeting.

Kimberly Butterwick, MD, and colleagues conducted a 6-month, double-blind, controlled multicenter study comparing Juvéderm Ultra (24 mg/mL hyaluronic acid, 0.3% lidocaine; HYC-24L, Allergan) with Belotero Balance (22.5 mg/ml hyaluronic acid; CPM-22.5, Merz Aesthetics) as treatment for 136 adults who had moderate-to-severe perioral lines. Patients’ mean age was 58 years. One hundred thirty-one patients completed the study.

Kimberly Butterwick, MD

Butterwick

The products were not diluted and came straight from the bottle, Butterwick said. Pain was measured before and after treatment, and bruising and Tyndall effect were measured after treatment.

A comparison of rater-assessed responder rates by a validated four-point Perioral Lines Severity Scale at 6 months was used as the study’s primary endpoint. Patients with a one-point improvement were defined as responders. The total volume injected was 1.18 cc for patients who received HYC-24L and 1.32 cc for patients who received CPM-22.5.

Eighty-seven percent of patients in the HYC-24L treatment arm reached endpoint compared with 72% of patients in the CPM-22.5 cohort. A significantly greater improvement in perioral lines was reported by patients treated with HYC-24L compared with those treated with CPM-22.5 at all times points, with the greatest difference between the two cohorts reported at 6 months (P < .001), according to the researchers. There were no unexpected adverse events. One Tyndall effect was reported in the CPM-22.5 cohort.

“Both products had a similar look, a natural feel and ease of injection, but HYC-24L provided more effective correction with less pain than CPM-22.5,” Butterwick said. “HYC’s greater persistence of effectiveness at month 6 suggests that it may exhibit a longer duration of benefit than CPM.” – by Bruce Thiel

Reference:

Butterwick K. Paper #F056. Late‐breaking Research: Surgical & Cosmetic. Presented at: American Academy of Dermatology Annual Meeting. March 20-24, 2015, San Francisco.

Disclosures: Butterwick and the other study investigators received research grants from Allergan.